Purpose: Both the AccuBoost ® D-shaped and round applicators have been dosimetrically 10 characterized and clinically used to treat patients with breast cancer. While the round applicators provide conformal dose coverage, under certain clinical circumstances the breast skin dose may be higher than preferred. The purpose of this study was to modify the round applicators to minimize skin dose while not substantially affecting dose uniformity within the target volume and reducing the treatment time.
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Methods: In order to irradiate the intended volume while sparing critical structures like the skin, the current round applicator design has been augmented through addition of an internal truncated cone (i.e., frustum) shield. Monte Carlo methods and clinical constraints were used to design the optimal cone applicator. With the cone applicator now defined as the entire assembly including the surrounding tungsten-alloy shell holding the HDR 192 Ir source catheter, 20 the applicator height was reduced to diminish the treatment time while minimizing skin dose. Monte Carlo simulation results were validated using both radiochromic film and ionization chamber measurements based on established techniques.
Results:
The optimal cone applicators diminished the maximum skin dose by 15% to 32% (based on applicator diameter and breast separation) with tumor dose reduced by less than 3%
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for a constant exposure time. Furthermore, reduction in applicator height diminished the treatment time by up to 30%. Radiochromic film and ionization chamber dosimetric results in phantom agreed with Monte Carlo simulation results typically within 3%. Larger differences were outside the treatment volume in low dose regions or associated with differences between the measurement and Monte Carlo simulation environments.
I. INTRODUCTION
The AccuBoost ® (Advanced Radiation Therapy LLC, Billerica, MA) D-shaped applicators and round applicators were designed to deliver HDR 192 Ir breast brachytherapy through collimation of emissions by an external shield. when using the AccuBoost ® applicators to deliver whole breast irradiation boost at 2 Gy per fraction for 10-16 Gy, it is possible that skin reactions such as moist skin desquamation may occur over the treated region. For accelerated partial breast irradiation (APBI) using this fractionation scheme, the maximum acceptable daily skin dose is less than 4.25 Gy based on nationwide observations of healthy tissue toxicities. Consequently, the design of the 50 AccuBoost ® applicators was reexamined to consider improvements for the superficial doses as would be delivered to the breast skin. For simplicity and due to their cylindrical symmetry, improvements of only the round applicators were considered.
For a single axis of treatment with the AccuBoost ® round applicators, the maximum dose is located on the surface of the breast skin. By adding of an internal tungsten-alloy shielding 55 device (i.e., truncated cone or frustum) inside the current round applicator, it is possible to irradiate the intended volume while diminishing the skin dose. By reducing the overall applicator height, it is also possible to reduce the treatment time. This study improves the clinical capabilities of the round applicators through Monte Carlo (MC) design optimization by reducing the skin dose and treatment time while retaining uniform tumor dose.
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II. MATERIALS AND METHODS
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II.A. Monte Carlo simulations
To guide the MC simulations for applicator design, an assessment of skin thickness was needed. Normal human skin is composed of epidermis layer, dermis layer and subcutaneous 65 layer. While breast skin thickness has been simulated as 4.0 mm thick for standardization of MC breast studies, 5,6 it is larger than the measured range. In a mammography study of 150 women, 7 the thickness of normal human breast skin was found to range from 0.8 -3.0 mm.
In a second study of 49 women using CT, the breast skin thickness, including epidermis layer and dermis layer, was measured to be 1.0 -2.2 mm. Consequently, the hypothesis of sparing breast skin while retaining uniform target dose seemed plausible. Based on the measured data and confidence intervals, a maximum breast skin thickness of 3.0 mm was used in this study with skin defined as 0 < d < 3.0 mm.
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The methods used to perform the MC simulations using MCNP5 version 1.40 radiation transport code 9 were similar to those used to characterize the dose distributions for the AccuBoost ® D-shaped and round applicators. 1,2 To determine the optimal frustum design for the interior shield, frustum variables were studied individually towards developing a cone applicator (Fig. 1) . The frustum was simulated ( Fig. 2a) To determine the optimal frustum design, r was simulated to align the cone edge -3.0 mm to 0.0 mm with 0.5 mm increments from the applicator internal aperture relative to the source dwell plane, h was simulated from 5.5 mm to 20.5 mm with 5.0 mm increments, and f was simulated to be 2.0 mm < f < 7.0 mm with 0.5 mm increments (an extreme value of f = 10.0 mm 90 was also simulated) Seven frustums with different r, four frustums with different h, and eleven frustums with different f were simulated for cone applicators having internal diameters of 4 cm to 8 cm (4C, 5C, 6C, 7C, and 8C), for comparisons to the round applicators (4R, 5R, 6R, 7R, and 8R). 2 The overall applicator height H was reduced by 3 mm to 18 mm after determining the optimal cone design, and was designed to balance the benefits of reduced skin dose and Towards estimating the variation of dosimetric results based on the practical nature of the applicator design, a sub-analysis of the applicator components (i.e., frustum, catheter, source) was performed to assess the effects of engineering tolerances. Frustum shift within the applicator aperture by 1 mm and 2 mm was calculated using a 2D *FMESH4 tally. and corresponded to the source positioned farthest from and closest to the skin, respectively.
II.B. Experimental measurements
After the optimal frustum geometry was determined using MC methods, the optimal 6C applicator (6R applicator + optimal frustum) was measured using both radiochromic film and ionization chamber. The measurement techniques were identical to those used previously for
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the AccuBoost ® D-shaped and round applicators.
1,2
Depth-dose data were measured using radiochromic type EBT film (International Specialty Products in Wayne, NJ) and measurements were converted to absorbed dose using film batch calibration. 
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The results from the Monte Carlo calculations and the radiochromic film measurements support this assumption.
To determine the depth of maximum dose, measurements were performed with 1 mm Table I . was extended to the other applicator diameters, and resulted in a trend of optimal frustum r design associated with applicator design guideline of internal radius minus 2 mm.
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III. RESULTS
III.A. Monte Carlo simulations
III.A.1. Optimal frustum design
Comparisons of dose profiles (Fig. 3b) were obtained for the other four applicator sizes. To avoid potential collision between the frustum and the compression paddle, the optimal frustum height (19.5 mm) was set to be 1 mm less than the maximum height in all cases, and did not significantly diminish the benefit of a 160 full-height h.
Comparisons of dose profiles (Fig. 3c) (Fig. 5) to the 6R skin/center dose ratios.
Over the full range of applicator diameters, optimal cone applicators reduced 
III.A.2. Height reduced applicator
The optimal cone applicators reduced 
III.A.3. Dosimetric variability
For the maximum and minimum changes in source shielding due to source positioning within the catheter and catheter guide, large differences were observed in the shadow of the frustum shield (45% at d ~ 0 mm on the central axis) and also outside the applicator aperture (19% at large depths) due to the frustum shielding angle where the relative dose rates are very 200 low. Otherwise, the dose differences due to source positioning were within 7% and explained by the inverse-square law.
Cylindrical symmetry of the applicator dose distribution was broken upon shifting the frustum. MC mesh tally results for 1 mm and 2 mm frustum shifts relative to the unshifted frustum results are shown in Fig. 2c for the optimal 6C applicator. On the d = 0 mm plane at 205 any one point, a maximum increase of 48% and maximum decrease of 53% was observed for the 1 mm frustum shift, with a maximum increase of 67% and maximum decrease of 86% for the 2 mm frustum shift. However, 
III.B. Radiochromic film
Radiochromic film results are shown in Fig. 6 . Depth-dose measurements along the central axis in PS from the radiochromic film were compared (Fig. 7a) to MC simulations for the 70 mm range for the 6R and 6C applicators. Differences exceeding 3% were observed for the 6C applicator for d < 7 mm, and may be explained due to differences between the idealized MC computational environment with the source centrally positioned within the catheter guide and the measurement environment where source positioning may have varied (section III.A.3).
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The film and MC results on the central axis differed by 8% at d = 7 mm and 16% at d = 0 mm, and were well within the potential 45% difference possible due to variable positioning of the source within the catheter guide. Dose profiles at d = 0 mm and d = 30 mm for the 6R and optimal 6C applicators (Fig. 7b) show agreement between film and MC results typically within 5% for both the 6R and 6C applicators. Larger differences were observed substantially 225 outside the field edge where the dose rates were lowest due to the previously mentioned influence of variable source positioning (section III.A.3).
III.C. Ion chamber
Depth-dose measurements along the central axis in PS from the ion chamber were compared (Fig. 7a) to MC simulations for the 6R and optimal 6C applicators. Agreement 230 typically within 3% was observed over the 0 < d < 70 mm range for the 6R applicator.
Differences exceeding 5% were observed for the 6C applicator for d < 8 mm. Based on the prior film analysis, it was evident that volume averaging within the ionization chamber led to the disparity. Upon volume averaging the MC results to mimic the spatial volume averaging of the ion chamber, the chamber:MC agreement improved to within 3% for 3 < d < 70 mm.
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IV. SUMMARY
Through design optimization using Monte Carlo methods for radiation transport simulations, 84782_3_art_file_474313_l8dzpz.doc Page 11 of 15 9/7/2010 the current round AccuBoost applicator was altered and its dosimetric properties were studied.
The main design change included an internal frustum positioned centrally within the round 240 applicator. The dimensions and resulting dosimetric influence of the frustum were studied individually. This new cone applicator exhibited substantial reduction (up to 32%) in maximum skin dose while not perturbing tumor dose uniformity and only minor reduction in total tumor dose for a fixed treatment time. Consequently, an additional parameter (applicator height) was also examined. The final design balanced the benefits of reduced skin dose (-10%) and mm and 30 mm depth obtained using Monte Carlo methods and radiochromic film for the optimal 6R applicator and 6C applicator.
